Perspective Therapeutics Presents at the World Molecular Imaging Congress 2024
Perspective Therapeutics (NYSE AMERICAN: CATX) presented updates on its alpha-particle radiopharmaceuticals at the World Molecular Imaging Congress 2024 in Québec, Canada. The company showcased two key presentations:
1. Preclinical evaluation of [203/212Pb]Pb-PSV-359 for imaging and alpha-particle therapy of cancers expressing fibroblast activation protein (FAP). The study demonstrated superior FAP binding affinity, strong tumor uptake, and anti-tumor effects in xenograft models.
2. Customizing chelators for targeted radionuclide therapy using computational modeling. The research highlighted the importance of matching chelators to specific radionuclides for optimal stability and targeted delivery in targeted radionuclide therapy (TRT).
CEO Thijs Spoor expressed satisfaction with the additional data supporting the development of their alpha-particle therapies, emphasizing the need for customized chelators and the favorable safety and efficacy profiles of their FAP-targeting candidate, PSV-359.
Perspective Therapeutics (NYSE AMERICAN: CATX) ha presentato aggiornamenti sui suoi radiofarmaci a particelle alpha al World Molecular Imaging Congress 2024 a Québec, Canada. L'azienda ha mostrato due presentazioni chiave:
1. Valutazione preclinica di [203/212Pb]Pb-PSV-359 per l'imaging e la terapia a particelle alpha di tumori esprimendo la proteina di attivazione dei fibroblasti (FAP). Lo studio ha dimostrato un'affinità di legame per il FAP superiore, un'elevata captazione tumorale e effetti anti-tumorali in modelli xenotrapianto.
2. Personalizzazione dei chelatori per la terapia con radionuclidi mirati utilizzando la modellazione computazionale. La ricerca ha evidenziato l'importanza di abbinare i chelatori a radionuclidi specifici per una stabilità ottimale e una somministrazione mirata nella terapia con radionuclidi mirati (TRT).
Il CEO Thijs Spoor ha espresso soddisfazione per i dati aggiuntivi che supportano lo sviluppo delle loro terapie a particelle alpha, sottolineando la necessità di chelatori personalizzati e i profili favorevoli di sicurezza ed efficacia del loro candidato-targeting FAP, PSV-359.
Perspective Therapeutics (NYSE AMERICAN: CATX) presentó actualizaciones sobre sus radiofármacos de partículas alfa en el Congreso Mundial de Imágenes Moleculares 2024 en Québec, Canadá. La empresa mostró dos presentaciones clave:
1. Evaluación preclínica de [203/212Pb]Pb-PSV-359 para la imagen y terapia con partículas alfa de cánceres que expresan la proteína de activación de fibroblastos (FAP). El estudio demostró una afinidad de unión a FAP superior, una fuerte captación tumoral y efectos anti-tumorales en modelos de xenoinjerto.
2. Personalización de quelantes para la terapia de radionúclidos dirigidos utilizando modelado computacional. La investigación destacó la importancia de adecuar los quelantes a radionúclidos específicos para una estabilidad óptima y una entrega dirigida en la terapia de radionúclidos dirigidos (TRT).
El CEO Thijs Spoor expresó satisfacción con los datos adicionales que respaldan el desarrollo de sus terapias con partículas alfa, enfatizando la necesidad de quelantes personalizados y los perfiles de seguridad y eficacia favorables de su candidato dirigido a FAP, PSV-359.
퍼스펙티브 테라퓨틱스 (NYSE AMERICAN: CATX)는 캐나다 퀘벡에서 열린 2024 세계 분자 영상 학회에서 알파 입자 방사선 의약품에 대한 업데이트를 발표했습니다. 이 회사는 두 가지 주요 발표를 선보였습니다:
1. 섬유아세포 활성화 단백질(FAP)을 발현하는 암의 이미징 및 알파 입자 치료를 위한 [203/212Pb]Pb-PSV-359의 전임상 평가. 이 연구는 FAP 결합 친화도가 우수하고, 종양 흡수량이 높으며, 이식 모델에서 항종양 효과를 나타냈습니다.
2. 계산 모델링을 사용하여 표적 방사성 동위원소 치료에 대한 킬레이터 맞춤형 제작. 이 연구는 최적의 안정성과 표적 방사성 동위원소 치료(TRT)를 위한 표적 전달을 위해 특정 방사성 동위원소에 킬레이터를 맞추는 것의 중요성을 강조했습니다.
CEO Thijs Spoor는 알파 입자 치료 개발을 지원하는 추가 데이터에 만족감을 표명하며, 맞춤형 킬레이터의 필요성과 FAP-타깃 후보인 PSV-359의 안전성 및 효능이 우수하다는 점을 강조했습니다.
Perspective Therapeutics (NYSE AMERICAN: CATX) a présenté des mises à jour sur ses radiopharmaceutiques à particules alpha lors du Congrès Mondial d'Imagerie Moléculaire 2024 à Québec, Canada. L'entreprise a présenté deux présentations clés :
1. Évaluation préclinique de [203/212Pb]Pb-PSV-359 pour l'imagerie et la thérapie à particules alpha des cancers exprimant la protéine d'activation des fibroblastes (FAP). L'étude a démontré une affinité de liaison au FAP supérieure, une forte captation tumorale et des effets anti-tumoraux dans des modèles de xénogreffe.
2. Personnalisation des chélateurs pour la thérapie par radionucléides ciblés en utilisant la modélisation computationnelle. La recherche a souligné l'importance d'adapter les chélateurs à des radionucléides spécifiques pour une stabilité optimale et une livraison ciblée dans la thérapie par radionucléides ciblés (TRT).
Le PDG Thijs Spoor a exprimé sa satisfaction quant aux données supplémentaires soutenant le développement de leurs thérapies à particules alpha, en soulignant la nécessité de chélateurs personnalisés et les profils de sécurité et d'efficacité favorables de leur candidat ciblant FAP, PSV-359.
Perspective Therapeutics (NYSE AMERICAN: CATX) hat beim World Molecular Imaging Congress 2024 in Québec, Kanada, Aktualisierungen seiner Alpha-Partikel-Radiofarmazeutika präsentiert. Das Unternehmen stellte zwei zentrale Präsentationen vor:
1. Präklinische Bewertung von [203/212Pb]Pb-PSV-359 für bildgebende Verfahren und Alpha-Partikel-Therapie von Krebsarten, die das Fibroblasten-Aktivierungsprotein (FAP) exprimieren. Die Studie zeigte eine überlegene FAP-Bindungsaffinität, starke Tumorpersistenz und anti-tumorale Effekte in Xenotransplantationsmodellen.
2. Anpassung von Chelatoren für die zielgerichtete Radionuklidtherapie durch computergestütztes Modellieren. Die Forschung hob die Bedeutung der Abstimmung von Chelatoren auf spezifische Radionuklide für optimale Stabilität und gezielte Abgabe in der zielgerichteten Radionuklidtherapie (TRT) hervor.
CEO Thijs Spoor äußerte Zufriedenheit mit den zusätzlichen Daten, die die Entwicklung ihrer Alpha-Partikel-Therapien unterstützen, und betonte die Notwendigkeit maßgeschneiderter Chelatoren sowie die günstigen Sicherheits- und Wirksamkeitsprofile ihres FAP-zielgerichteten Kandidaten PSV-359.
- Preclinical studies show PSV-359 has superior FAP binding affinity and specificity
- PSV-359 demonstrates strong tumor uptake and clearance from the blood
- [212Pb]Pb-PSV-359 shows strong anti-tumor effects in xenograft models
- Computational modeling confirms modified chelators' superior performance in targeted radionuclide therapy
- None.
SEATTLE, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced updates featuring the Company’s alpha-particle radiopharmaceuticals at the World Molecular Imaging Congress (WMIC) 2024, held on September 9-13, 2024, in Québec, Canada.
“We are pleased with the additional data that support the continued development of our alpha-particle therapies,” said Thijs Spoor, Perspective Therapeutics' CEO. “The data demonstrate the need for customized chelators to maximize stability and targeted delivery of potent alpha-particles. Additionally, our novel FAP-targeting candidate, PSV-359, continues to show favorable safety and strong efficacy profiles in preclinical studies.”
Presentation One: Preclinical evaluation of [203/212Pb]Pb-PSV-359 for imaging and alpha-particle therapy of cancers expressing fibroblast activation protein (FAP)**
Summary: The objective of this study is to evaluate [203/212Pb]Pb-radiolabeled PSV-359 in vitro and in vivo. PSV359 comprises a novel cyclic peptide targeting human FAP (hFAP), and a molecular linker to a lead-specific chelator. The researcher found that in vitro, [203/212Pb]Pb-PSV-359 demonstrated superior FAP binding affinity and specificity, and that [203Pb]Pb-PSV-359 showed strong tumor uptake and clearance from the blood via the renal system. In the study, [212Pb]Pb-PSV-359 also showed strong anti-tumor effects in xenograft models in which FAP was either on cancer cells or in stromal tissues.
Presenter: Brianna S. Cagle, PhD, Research Scientist, Perspective Therapeutics
Presentation Two: Customizing chelators for targeted radionuclide therapy: Insights from computational modeling
Summary: Researchers demonstrated the use and importance of computational methods to guide customization of chelators. They found that appropriate matching of the chelator to the specific radionuclide to ensure stability and targeted delivery is integral to the success of targeted radionuclide therapy (TRT). With the support of computational modeling, the investigators used multiple chelators that are commonly used in TRT, along with alpha emitters, beta emitters, and imaging tracers to determine compatibility between chelators and radionuclides. The study confirmed that modified chelators demonstrated superior performance when compared to conventional chelators.
Presenter: Jeongyun Kim, Doctoral Student, Seoul National University
**Presentation selected to be featured in the highlights of the closing lecture.
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides, which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary 212Pb generator to secure key isotopes for clinical trial and commercial operations.
For more information, please visit the Company's website at www.perspectivetherapeutics.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include express or implied statements concerning, among other things, the Company’s ability to pioneer advanced treatment applications for cancers throughout the body; expectations regarding the timing and advancement of the Company’s clinical and preclinical programs; the potential for customized chelators to maximize stability and targeted delivery of alpha-particles; the FAP binding affinity and specificity of [203/212Pb]Pb-PSV-359; the potential safety and efficacy of the Company’s FAP-targeting candidate, PSV-359; the potential for [212Pb]Pb-PSV-359 to offer strong tumor uptake and clearance from the blood and strong anti-tumor effects; the potential for the application of computational modeling to the customization of chelators to enhance matching of chelators to specific radionuclides; the ability of the Company’s proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides; the opportunity to personalize treatment and optimize patient outcomes using the Company’s complementary imaging diagnostics that incorporate the same targeting peptides; the Company's expectation that its "theranostic" approach enables the ability to see specific tumors and then treat them to potentially improve efficacy and minimize toxicity; the Company’s ability to develop a proprietary 212Pb generator to secure key isotopes for clinical trial and commercial operations; expectations regarding the potential market opportunities for the Company’s product candidates; the potential functionality, capabilities, and benefits of the Company’s product candidates and the potential application of these product candidates for other disease indications; the Company’s expectations, beliefs, intentions, and strategies regarding the future; the Company’s intentions to improve important aspects of care in cancer treatment; and other statements that are not historical fact.
The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company’s actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company’s actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”), in the Company’s other filings with the SEC, and in the Company’s future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
FAQ
What did Perspective Therapeutics (CATX) present at the World Molecular Imaging Congress 2024?
What were the key findings of the PSV-359 study presented by Perspective Therapeutics (CATX)?
How did computational modeling benefit Perspective Therapeutics' (CATX) chelator research?
What did CEO Thijs Spoor say about Perspective Therapeutics' (CATX) alpha-particle therapies?
